Covered recipient · General Payments record
ROBERT D FISHBERG
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$26,603.43
149 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,872.53 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,600.00 | 2 |
| Food and Beverage | $2,935.54 | 138 |
| Travel and Lodging | $1,195.36 | 5 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ionis Pharmaceuticals, Inc. | $13,755.04 | 14 |
| Amgen Inc. | $6,260.02 | 24 |
| Regeneron Healthcare Solutions, Inc. | $4,727.82 | 8 |
| Novartis Pharmaceuticals Corporation | $298.33 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $170.79 | 4 |
| E.R. Squibb & Sons, L.L.C. | $162.72 | 19 |
| Edwards Lifesciences Corporation | $150.31 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $149.92 | 7 |
| Merck Sharp & Dohme LLC | $135.35 | 8 |
| Regeneron Pharmaceuticals, Inc. | $120.45 | 3 |
| Novo Nordisk Inc | $109.25 | 6 |
| PFIZER INC. | $103.75 | 6 |
| Lilly USA, LLC | $69.50 | 4 |
| AstraZeneca Pharmaceuticals LP | $50.81 | 3 |
| BridgeBio Pharma, Inc. | $50.72 | 3 |
| Chiesi USA, Inc. | $49.16 | 2 |
| Esperion Therapeutics, Inc. | $44.68 | 3 |
| Baxter Healthcare | $37.18 | 1 |
| Alnylam Pharmaceuticals Inc. | $37.14 | 2 |
| Boston Scientific Corporation | $34.34 | 1 |
| AGEPHA Pharma FZ LLC | $32.51 | 1 |
| ENDOTRONIX, INC. | $31.08 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $22.56 | 1 |
Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT D FISHBERG
NPI 1871587345 · CMS profile ID 176292
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
SPRINGFIELD, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
149 matching records · $26,603.43 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–149 of 149.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4.46 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208144 | CMS |
| Alnylam Pharmaceuticals Inc. | $18.66 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212788400 | CMS |
| Merck Sharp & Dohme LLC | $16.32 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238375312 | CMS |
| Lilly USA, LLC | $15.86 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186901202 | CMS |
| Amgen Inc. | $13.92 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227230156 | CMS |
| Amgen Inc. | $125.00 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228540213 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.88 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801241 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6.71 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801231 | CMS |
| Boston Scientific Corporation | $34.34 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181419036 | CMS |
| Novartis Pharmaceuticals Corporation | $13.61 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208140 | CMS |
| Esperion Therapeutics, Inc. | $14.62 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243958388 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.59 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225537041 | CMS |
| Regeneron Pharmaceuticals, Inc. | $41.25 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237805 | CMS |
| Merck Sharp & Dohme LLC | $15.48 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238157553 | CMS |
| Novartis Pharmaceuticals Corporation | $4.54 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208142 | CMS |
| Novo Nordisk Inc | $18.87 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188223595 | CMS |
| Amgen Inc. | $19.19 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228540211 | CMS |
| Baxter Healthcare | $37.18 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181559894 | CMS |
| Novartis Pharmaceuticals Corporation | $18.11 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208138 | CMS |
| Edwards Lifesciences Corporation | $150.31 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225244865 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.62 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801217 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.10 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212920104 | CMS |
| Novartis Pharmaceuticals Corporation | $4.71 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208132 | CMS |
| Novartis Pharmaceuticals Corporation | $1.34 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208134 | CMS |
| PFIZER INC. | $17.00 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231404835 | CMS |
| Amgen Inc. | $103.90 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228540215 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.85 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801205 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.90 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212920102 | CMS |
| ENDOTRONIX, INC. | $31.08 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239001912 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801209 | CMS |
| PFIZER INC. | $16.06 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231376318 | CMS |
| Regeneron Healthcare Solutions, Inc. | $732.75 | 02/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212920098 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,908.00 | 02/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212920100 | CMS |
| Amgen Inc. | $2,800.00 | 02/20/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226889101 | CMS |
| Amgen Inc. | $5.54 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227230142 | CMS |
| Amgen Inc. | $89.38 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228540223 | CMS |
| Lilly USA, LLC | $16.53 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186881111 | CMS |
| Chiesi USA, Inc. | $21.88 | 02/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242159253 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.13 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801189 | CMS |
| Novartis Pharmaceuticals Corporation | $15.69 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208136 | CMS |
| Novo Nordisk Inc | $18.78 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188545452 | CMS |
| Amgen Inc. | $13.92 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227230148 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.02 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225537039 | CMS |
| Merck Sharp & Dohme LLC | $18.25 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238064804 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.72 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223067049 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.97 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206276024 | CMS |
| Novo Nordisk Inc | $18.96 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188736577 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1.47 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801175 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.78 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184801177 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $804,076.31 | 19 |
| PY2024 | Recipient | $33,559.00 | 1 |
| PY2024 | Principal investigator | $292,861.28 | 14 |
| PY2023 | Principal investigator | $249,132.65 | 7 |
| PY2022 | Principal investigator | $238,922.01 | 4 |
| PY2021 | Principal investigator | $167,569.21 | 11 |
| PY2020 | Principal investigator | $40,813.46 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
19 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,493.48 | 12/16/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190297238 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,744.00 | 11/24/2025 | Non-covered Recipient Entity ATLANTIC HEALTH SYSTEM DBA ATLANTIC CORPORATE HEALTH DEPARTMENT OF ATLANTIC CORPORATE HEALTH | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190309416 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $286.56 | 10/27/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190297235 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $935.54 | 10/17/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190297231 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38.19 | 10/03/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190297242 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $492.48 | 09/29/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190294233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,747.28 | 09/24/2025 | Non-covered Recipient Entity OVERLOOK FOUNDATION | ATLANTIC LIPID LOWERING TREATMENT OPTIMIZATION PROGRAM (ALLTOP): A COMPREHENSIVE APPROACH TO ADDRESSING DYSLIPIDEMIA AND COMORBIDITIES AMONG HIGH-RISK PATIENTS | No dispute reported | 06/30/2026 | 1184241964 |
| Principal investigator 1 | Eli Lilly and Company | $165.35 | 09/19/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187884692 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $60,328.48 | 05/27/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C | No dispute reported | 06/30/2026 | 1190294226 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,697.10 | 02/19/2025 | Non-covered Recipient Entity GORYEB CHILDRENS HOSPITAL AT MORRISTOWN MEMORIAL | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190303857 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36,790.10 | 02/04/2025 | Covered Recipient Teaching Hospital Morristown Medical Center | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190297073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,747.28 | 01/29/2025 | Non-covered Recipient Entity OVERLOOK FOUNDATION | ATLANTIC LIPID LOWERING TREATMENT OPTIMIZATION PROGRAM (ALLTOP): A COMPREHENSIVE APPROACH TO ADDRESSING DYSLIPIDEMIA AND COMORBIDITIES AMONG HIGH-RISK PATIENTS | No dispute reported | 06/30/2026 | 1184149810 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58,401.57 | 01/28/2025 | Covered Recipient Teaching Hospital Morristown Medical Center | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190297070 |
| Principal investigator 1 | Amgen Inc. | $119,884.93 | 01/21/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246637884 |
| Principal investigator 1 | Eli Lilly and Company | $4,145.10 | 01/20/2025 | Covered Recipient Teaching Hospital MORRISTOWN MEDICAL CENTER | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187873127 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,682.48 | 01/15/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190294219 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,220.53 | 01/15/2025 | Covered Recipient Teaching Hospital Overlook Medical Center | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190294223 |
| Principal investigator 1 | Eli Lilly and Company | $241,033.00 | 01/07/2025 | Covered Recipient Teaching Hospital MORRISTOWN MEDICAL CENTER | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187874923 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $79,242.86 | 01/07/2025 | Covered Recipient Teaching Hospital Morristown Medical Center | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190297065 |